Aspirin Dose Upregulation Fails After Acute Coronary Syndrome 09/01/25
Welcome to Cardiology Today â Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like acute coronary syndrome and aspirin resistance. Key takeaway: Aspirin Dose Upregulation Fails After Acute Coronary Syndrome.
Article Links:
Article 1: Outcomes of cardiovascular screening in men aged 60-64 years: the DANCAVAS II trial. (European heart journal)
Article 2: Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial. (European heart journal)
Article 3: Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-Difference trial. (European heart journal)
Article 4: Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial. (European heart journal)
Article 5: High-dose vs. standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial. (European heart journal)
Tap ‘more’ for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/aspirin-dose-upregulation-fails-after-acute-coronary-syndrome-09-01-25/
đ Full Episode Summary
This episode covers recent research from top journals like NEJM and JACC. Tap ‘more’ for details.
đ Featured Articles
Article 1: Outcomes of cardiovascular screening in men aged 60-64 years: the DANCAVAS II trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884758
Summary: This randomized controlled trial investigated cardiovascular disease screening in men aged 60 to 64. The study found no significant difference in all-cause mortality between the screening group and the control group after a median follow-up of 6.7 years, suggesting that this type of screening may not reduce mortality in this population.
Article 2: Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884757
Summary: The ANDAMAN trial investigated twice-daily versus once-daily aspirin in acute coronary syndrome patients with diabetes mellitus or high-risk aspirin resistance. Results showed no significant difference in major adverse cardiovascular events between the two aspirin dosing regimens at 12 months. This indicates that, in this population, escalating aspirin dosage does not reduce ischemic events.
Article 3: Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-Difference trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884558
Summary: The VICTORION-Difference trial, a phase three trial, demonstrated that inclisiran, a small interfering ribonucleic acid targeting proprotein convertase subtilisin/kexin type 9 messenger ribonucleic acid, significantly reduced low-density lipoprotein cholesterol levels when added to usual care in patients with hypercholesterolemia. This suggests inclisiran is an effective treatment strategy for lowering low-density lipoprotein cholesterol and has the potential to improve cardiovascular outcomes in this population.
Article 4: Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884439
Summary: This secondary analysis of the DAN-RSV trial evaluated the bivalent respiratory syncytial virus prefusion F protein-based vaccine’s effectiveness on respiratory and cardiovascular outcomes in adults with and without atherosclerotic cardiovascular disease. The respiratory syncytial virus vaccine showed a significant reduction in respiratory syncytial virus related lower respiratory tract disease, but no statistically significant effect on cardiovascular events, suggesting targeted respiratory protection.
Article 5: High-dose vs. standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884413
Summary: standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial. The DANFLU-2 trial compared high-dose versus standard-dose inactivated influenza vaccine in adults with and without atherosclerotic cardiovascular disease. The study showed no significant difference in cardiovascular or respiratory outcomes between the two vaccine doses. This indicates that high-dose influenza vaccination does not provide superior cardiovascular protection compared to standard-dose in this population.
đ Transcript
Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Outcomes of cardiovascular screening in men aged 60-64 years: the DANCAVAS II trial. This randomized controlled trial investigated cardiovascular disease screening in men aged 60 to 64. The study found no significant difference in all-cause mortality between the screening group and the control group after a median follow-up of 6.7 years, suggesting that this type of screening may not reduce mortality in this population.Article number two. Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial. The ANDAMAN trial investigated twice-daily versus once-daily aspirin in acute coronary syndrome patients with diabetes mellitus or high-risk aspirin resistance. Results showed no significant difference in major adverse cardiovascular events between the two aspirin dosing regimens at 12 months. This indicates that, in this population, escalating aspirin dosage does not reduce ischemic events.Article number three. Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-Difference trial. The VICTORION-Difference trial, a phase three trial, demonstrated that inclisiran, a small interfering ribonucleic acid targeting proprotein convertase subtilisin/kexin type 9 messenger ribonucleic acid, significantly reduced low-density lipoprotein cholesterol levels when added to usual care in patients with hypercholesterolemia. This suggests inclisiran is an effective treatment strategy for lowering low-density lipoprotein cholesterol and has the potential to improve cardiovascular outcomes in this population.Article number four. Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial. This secondary analysis of the DAN-RSV trial evaluated the bivalent respiratory syncytial virus prefusion F protein-based vaccine’s effectiveness on respiratory and cardiovascular outcomes in adults with and without atherosclerotic cardiovascular disease. The respiratory syncytial virus vaccine showed a significant reduction in respiratory syncytial virus related lower respiratory tract disease, but no statistically significant effect on cardiovascular events, suggesting targeted respiratory protection.Article number five. High-dose vs. standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial. The DANFLU-2 trial compared high-dose versus standard-dose inactivated influenza vaccine in adults with and without atherosclerotic cardiovascular disease. The study showed no significant difference in cardiovascular or respiratory outcomes between the two vaccine doses. This indicates that high-dose influenza vaccination does not provide superior cardiovascular protection compared to standard-dose in this population.
Thank you for listening. Tap ‘more’ for full notes and links.
đ Keywords
acute coronary syndrome, aspirin resistance, antiplatelet therapy, inclisiran, low-density lipoprotein cholesterol, hypercholesterolemia, vaccine, respiratory syncytial virus, diabetes mellitus, mortality, screening, coronary artery calcification, atherosclerotic cardiovascular disease, respiratory tract infection, respiratory outcomes, cardiovascular disease, influenza vaccine, proprotein convertase subtilisin/kexin type 9, cardiovascular outcomes.
âšī¸ About
Concise summaries of cardiovascular research for professionals.
Subscribe âĸ Share âĸ Follow